June 21st, 2022

InOrbitTX FXR patent now also granted in the US and China.

After getting granted in the EU and South-Korean, now InOrbitTX’s patent “COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME” got granted in te US and China as well.  Again a very important step towards global protection of InOrbitTX’s rights

Feb 10th, 2022

After EPO, now the S-Korean patent office grants patent rights to InOrbitTX’s FXR patent.

After the EPO granted patent rights in Dec ’21, and after InorbitTX for got a notice that the US patent office intends to grant rights in Jan, now the S-Korean office granted patent rights to InOrbitTX’ patent application: “COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME”.  Yet another significant step towards global protection of InOrbitTX’s rights.

Jan 26th, 2022

United States Patent and Trademark Office issues letter of intend for InOrbitTX FXR patent

The US patent and trademark office notified InOrbitTX that it intends to grant patent right to its patent application “COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME”.  Another step in global right protection.

Dec 18th, 2021

EPO grants InOrbiTX patent rights

InOrbitTXwas just notified by the European Patent Office that its patent: “COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME” was granted.  A first step in global protection of the rights to its very promising candidate drug, the FXR agonist IOT022.

Dec 11th, 2019

InorbitTX and Cereno Scientific enter into a licensing agreement

InorbitTx and Cereno Scientific announce a licensing agreement for IOT032, now CS036, for cardiovascular diseases.  Please read the full article on BioStock here.

Oct 26th, 2019

InorbitTX presented at the China Biomedical Forum.

Bert Benthem (CEO) was invited to present at the China (Shenzhen) Biomedical Industry Cooperation Forum, Oct 25 – 27 2019 in Shenzhen, China, with key participation from Medical and Pharmaceutical Academia, Presidents of Hospitals and Public Pharmaceuticals, Chairmen of Investment Firms, and Directors of Medical Parks.

Oct 9th, 2019

InorbitTX to attend Bio-Europe  in Hamburg, Germany

Robert Judkins(CSO) will attend Bio-Europe, Nov 11 – 13, in Hamburg, Germany.  Robert is happy to meet you there to explore the possibilities for collaborations, alliances, and investment.

Aug 19th, 2019

InorbitTX was invited to present at the China (Rizhao) Biomedical Industry Forum.

Bert Benthem (CEO) was invited to present at the China (Rizhao) Biomedical Industry Cooperation Forum, co-sponsored by the China Biotechnology Association and Beijing Fukangren Bio-Pharma Ltd., on Aug 8th, 2019.

Nov 8th, 2018

InorbitTX covered by Medwatch

InorbitTX got coverage in the Danish biotech and life science media (Medwatch.dk):
‘Tidligere Novo Nordisk-forsker vil opbygge pipeline af fedtlevermidler billigt og hurtigt.’
https://medwatch.dk/Medicinal___Biotek/article10989545.ece